Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2015 1
2016 1
2017 1
2018 1
2019 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacological chaperones for human alpha-N-acetylgalactosaminidase.
Clark NE, Metcalf MC, Best D, Fleet GW, Garman SC. Clark NE, et al. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17400-5. doi: 10.1073/pnas.1203924109. Epub 2012 Oct 8. Proc Natl Acad Sci U S A. 2012. PMID: 23045655 Free PMC article.
Schindler/Kanzaki disease is an inherited metabolic disease with no current treatment options. This neurologic disease results from a defect in the lysosomal alpha-N-acetylgalactosaminidase (alpha-NAGAL) enzyme. ...
Schindler/Kanzaki disease is an inherited metabolic disease with no current treatment options. This neurologic
The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases.
Naumchik BM, Gupta A, Flanagan-Steet H, Steet RA, Cathey SS, Orchard PJ, Lund TC. Naumchik BM, et al. Cells. 2020 Jun 5;9(6):1411. doi: 10.3390/cells9061411. Cells. 2020. PMID: 32517081 Free PMC article. Review.
The glycoprotein disorders are a group of lysosomal storage diseases (alpha-mannosidosis, aspartylglucosaminuria, beta-mannosidosis, fucosidosis, galactosialidosis, sialidosis, mucolipidosis II, mucolipidosis III, and Schindler Disease) characterized by speci …
The glycoprotein disorders are a group of lysosomal storage diseases (alpha-mannosidosis, aspartylglucosaminuria, beta-mannosidosis, …
Exploration of Structural and Functional Variations Owing to Point Mutations in alpha-NAGA.
Meshach Paul D, Rajasekaran R. Meshach Paul D, et al. Interdiscip Sci. 2018 Mar;10(1):81-92. doi: 10.1007/s12539-016-0173-8. Epub 2016 May 2. Interdiscip Sci. 2018. PMID: 27138754
Schindler disease is a lysosomal storage disorder caused due to deficiency or defective activity of alpha-N-acetylgalactosaminidase (alpha-NAGA). Mutations in gene encoding alpha-NAGA cause wide range of diseas
Schindler disease is a lysosomal storage disorder caused due to deficiency or defective activity of alpha-N
A Novel Homozygous Missense Variant in the NAGA Gene with Extreme Intrafamilial Phenotypic Heterogeneity.
Mohamed FE, Al Sorkhy M, Ghattas MA, Al-Zaabi N, Al-Shamsi A, Almansoori TM, Al-Gazali L, Al-Dirbashi OY, Al-Jasmi F, Ali BR. Mohamed FE, et al. J Mol Neurosci. 2020 Jan;70(1):45-55. doi: 10.1007/s12031-019-01398-6. Epub 2019 Aug 29. J Mol Neurosci. 2020. PMID: 31468281
Schindler disease is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in alpha-N-acetylgalactosaminidase (alpha-NAGA) activity due to defects in the NAGA gene. ...Both the proband and his s
Schindler disease is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in alpha-N
Application of ion mobility tandem mass spectrometry to compositional and structural analysis of glycopeptides extracted from the urine of a patient diagnosed with Schindler disease.
Sarbu M, Zhu F, Peter-Katalinić J, Clemmer DE, Zamfir AD. Sarbu M, et al. Rapid Commun Mass Spectrom. 2015 Nov 15;29(21):1929-37. doi: 10.1002/rcm.7288. Rapid Commun Mass Spectrom. 2015. PMID: 26443390
RATIONALE: Schindler disease is caused by the deficient activity of alpha-N-acetylgalactosaminidase, which leads to an abnormal accumulation of O-glycopeptides in tissues and body fluids. ...The structural analysis by CID MS/MS in combination wi …
RATIONALE: Schindler disease is caused by the deficient activity of alpha-N-acetylgalactosaminidase, whic …
Automated chip-nanoelectrospray mass spectrometry for glycourinomics in Schindler disease type I.
Sarbu M, Robu A, Peter-Katalinić J, Zamfir AD. Sarbu M, et al. Carbohydr Res. 2014 Oct 29;398:90-100. doi: 10.1016/j.carres.2014.08.014. Epub 2014 Sep 6. Carbohydr Res. 2014. PMID: 25243357
In this study an integrative mass spectrometry (MS) approach based on fully automated chip-nanoelectrospray quadrupole time-of-flight was optimized and applied for the discovery and structural characterization of O-glycopeptides in a fraction from the urine of a patient diagnosed …
In this study an integrative mass spectrometry (MS) approach based on fully automated chip-nanoelectrospray quadrupole time-of-flight was op …
Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses.
Piraud M, Pettazzoni M, Menegaut L, Caillaud C, Nadjar Y, Vianey-Saban C, Froissart R. Piraud M, et al. Rapid Commun Mass Spectrom. 2017 Jun 15;31(11):951-963. doi: 10.1002/rcm.7860. Rapid Commun Mass Spectrom. 2017. PMID: 28370531
In urine, it allows not only the identification of all the oligosaccharidoses previously identified by TLC (fucosidosis, alphamannosidosis, aspartylglucosaminuria, GM1 gangliosidosis, sialidosis, galactosialidosis and Schindler disease), but also extends the field o …
In urine, it allows not only the identification of all the oligosaccharidoses previously identified by TLC (fucosidosis, alphamannosidosis, …
A capillary electrophoresis procedure for the screening of oligosaccharidoses and related diseases.
Casado M, Altimira L, Montero R, Castejón E, Nascimento A, Pérez-Dueñas B, Ormazabal A, Artuch R. Casado M, et al. Anal Bioanal Chem. 2014 Jul;406(18):4337-43. doi: 10.1007/s00216-014-7832-6. Epub 2014 May 2. Anal Bioanal Chem. 2014. PMID: 24788891
Abnormal peaks with slower migration times than the tetrasaccharide position were observed for fucosidosis, alpha-mannosidosis, GM1 gangliosidosis, GM2 gangliosidosis variant 0, Pompe disease, and glycogen storage disease type 3. ...In all of the cases, the u …
Abnormal peaks with slower migration times than the tetrasaccharide position were observed for fucosidosis, alpha-mannosidosis, GM1 g …